Translating disease biology into new diagnostic applications holds great promise for improving outcome for patients. We characterize gastrointestinal (pre)-malignant lesions by molecular (DNA, RNA, protein) profiling for biomarker development, to improve colorectal cancer screening as well as to stratify patient groups and arrive at individually tailored therapies.
Disease biology is studied using organoid cultures as pre-clinical model systems. Clinical validation is performed using well-defined patient cohort sample series derived from screening programs and multi-center clinical trials.
